Neuropeptide Y T1128C polymorphism: An independent predictor of hypertensive and cardiovascular diseases?

Journal of Hypertension

Volumn 22, Issue 7, 2004, Pages 1251-1253

  Zhuo, Jia L ^a  

^a HENRY FORD HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DNA SEQUENCE; EDITORIAL; GENETIC CODE; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; STROKE;

EID: 3042831509     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000125471.35523.ad     Document Type: Editorial

References (26)

1. Michel MC, Rascher W. Neuropeptide Y: a possible role in hypertension? J Hypertens 1995; 13:385-395.
2. Tatemoto KM, Carlquist M, Mutt V. Neuropeptide Y: a novel brain peptide with structural similarities to peptide YY and pancreatic peptide. Nature 1982; 296:659-660.
3. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, et al. Neuropeptide Y distribution in the rat brain. Science 1983; 221:877-879.
4. Odar-Cederlof I, Ericsson F, Theodorsson E, Kjellstrand CM. Is neuropeptide Y a contributor to volume-induced hypertension? Am J Kidney Dis 1998; 31:803-808.
5. Zukowska Z, Pons J, Lee EW, Li L. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 2003; 81:89-94.
6. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell Mol Life Sci 2003; 60:350-377.
7. Prosta L, Qu J, Robinson RB. Neuropeptide Y: neurotransmitter or trophic factor in the heart? News Physiol Sci 2003; 18:181-185.
8. Bell D, Allen AR, Kelso EJ, Balasubramaniam A, McDermott BJ. Induction of hypertrophic responsiveness of cardiomyocytes to neuropeptide Y in response to pressure overload. J Pharmacol Exp Ther 2002; 303:581-591.
9. Wallerstedt S, Skrtic S, Eriksson A-L, Ohlsson C, Hedner T. Association analysis of the polymorphism T1128C in signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 2004; 22:1277-1281.
10. Minth CD, Andrews PC, Dixon JE. Characterization, sequence, and expression of the cloned human neuropeptide Y gene. J Biol Chem 1986; 261:11974-11979.
11. Takeuchi T, Gumucio D, Meisler M, Minth C, Dixon J, Eddy R, et al. Genes encoding pancreatic polypeptide and neuropeptide Y are on human chromosomes 17 and 7. J Clin Invest 1986; 77:1038-1041.
12. Baker E, Hort YJ, Ball H, Sutherland GR, Shine J, Herzog H. Assignment of the human neuropeptide Y gene to chromosome 7p15.1 by nonisotopic in situ hybridization. Genomics 1995; 26:163-164.
13. Katsuya T, Higaki J, Zhao Y, Miki T, Mikami H. Serikawa T, Ogihara T. A neuropeptide Y locus on chromosome 4 cosegregates with blood pressure in the spontaneously hypertensive rats. Biochem Biophys Res Commun 1993; 192:261-267.
14. Herzog H, Selbie LA, Zee RYL, Morris BJ, Shine J. Neuropeptide Y Y1 receptor gene polymorphism: cross-sectional analysis in essential hypertension and obesity. Biochem Biophys Res Commun 1993; 196:902-906.
15. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998; 4:1434-1437.
16. Uusitupa MI, Karvonen MK, Pesonen U, Koulu M. Neuropeptide Y: a novel link between the neuroendocrine system and cholesterol metabolism. Ann Med 1998; 30:508-510.
17. Pettersson-Fernholm K, Karvonen MK, Kallio J, Forsblom CM, Koulu M, Pesonen U, et al. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diabetes Care 2004; 27:503-509.
18. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen MK, Valve R, Pesonen U, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2000; 108:235-236.
19. Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 2000; 85:2266-2269.
20. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, et al. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001; 159:145-151.
21. Erkkila AT, Lindi V, Lento S, Laakso M, Uusitupa MI. Association of leucine 7 to proline polymorphism in the preproneuropeptide Y with serum lipids in patients with coronary heart disease. Mol Genet Metab 2002; 75:260-264.
22. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353:611-616.
23. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ichihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphism in candidate genes. N Engl J Med 2002; 347:1916-1923.
24. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Trans 2003; 110:1199-1204.
25. Jarvisalo MJ, Jartti L, Karvonen MK, Pesonen U, Koulu M, Marniemi J, et al. Enhanced endothelium-dependent vasodilation in subjects with proline 7 substitution in the signal peptide of neuropeptide Y. Atherosclerosis 2003; 167:319-326.
26. Kallio J, Pesonen U, Jaakkola U, Karvonen MK, Helenius H, Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the preproneuropeptide Y. J Clin Endocrinol Metab 2003; 88:3278-3283.